Quest Diagnostics stock holds near highs after Q2 beat
Published on 08/21/2026 at 18:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Quest Diagnostics Inc. (ISIN US74834L1008) stock is still trading close to its recent high after second-quarter 2026 revenue reached $3.04 billion and adjusted EPS came in at $3.12. The latest market snapshot in the result set shows the shares at $241.80, with a market cap of $26.69 billion and a 52-week high of $245.68.
Quarterly beat drives the setup
The quarter ended June 30, 2026, delivered 10.2% year-over-year revenue growth, and EPS beat the $2.82 consensus by $0.30. That combination matters because it pairs a top-line gain with a margin story that still supports earnings power into fiscal 2026.
Guidance also gives the stock a concrete anchor: fiscal 2026 EPS is guided to $11.05-$11.25, while analysts in the same coverage set expect $11.15 for the year. The spread is narrow, which leaves the latest quarter as the main evidence that the outlook is holding up.
Valuation stays firm
The current quote data in the results show a price of $241.80 and a trailing price-to-earnings ratio of 25.67, versus a 52-week low of $171.18 and a 52-week high of $245.68. That puts the stock within 1.6% of the top of its reported range, a sign that the market is already discounting much of the 2026 earnings momentum.
Consensus remains constructive but not aggressive. The average target is $235.31, while several brokerage notes in the result set sit between $245 and $260, which gives the stock a valuation band rather than a single clean consensus level.
Diagnostics demand still matters
Quest Diagnostics runs a broad diagnostics network spanning routine laboratory testing, anatomic pathology, molecular diagnostics, infectious disease testing, and toxicology. In this setup, the most important product is not a single assay but the scale of the testing platform itself, because Q2 2026 showed that higher demand can still translate into a 10.2% revenue gain.
The business mix also supports a steadier earnings profile than many healthcare names because reimbursement, volume, and test mix all feed into the same operating engine. That is why the quarter's EPS beat and the full-year EPS guidance matter more than a generic sector story.
Quest Diagnostics stock level
Quest Diagnostics stock last traded at $241.80, according to the market snapshot in the result set, with the quote carrying a market cap of $26.69 billion. The shares are priced just below the reported 52-week high of $245.68 and above the 2026 starting level implied by the same coverage set.
Fact box
Company: Quest Diagnostics Inc.
ISIN: US74834L1008
Ticker: DGX
Exchange: New York Stock Exchange
Price (as of August 21, 2026): $241.80 USD
Market cap: $26.69 billion (as of August 21, 2026)
Sector / Industry: Health Care - Diagnostics and Research
Index membership: S&P 500
